RSV Immunization Significantly Reduces Hospitalizations in Infants

A new immunization against Respiratory Syncytial Virus (RSV) is demonstrating a significant impact on hospitalization rates among infants, according to pediatricians at Flevo Hospital in the Netherlands. Since the introduction of the RSV shot as part of the National Vaccination Program in September 2025, the hospital has seen a marked decrease in severe cases requiring pediatric intensive care unit (ICU) admissions.

Dramatic Reduction in ICU Transfers

Prior to the immunization program, Flevo Hospital frequently had to transfer critically ill babies to pediatric ICUs in other cities due to capacity constraints. Roy Zuurbier, a pediatrician in training and researcher at Flevo Hospital, noted, “This has not been necessary once this season, which is very special. During the peak of previous seasons, up to three children sometimes had to be transferred in one week.” Doctors within the department have likewise observed a substantial difference, reporting fewer instances of needing to transfer patients to other hospitals due to overcrowding.

How the RSV Shot Works

The new RSV immunization differs from traditional vaccines. Instead of prompting the body to develop its own antibodies, it provides immediate protection by directly administering antibodies to the baby. Zuurbier explains, “The antibodies protect the child against the virus for about six months. The child does not have to produce antibodies itself and therefore does not grow ill. The effect is almost immediate.” This approach results in minimal side effects, typically limited to mild redness at the injection site.

Preventing Severe Illness, Not Eradicating the Virus

The primary goal of the immunization is to prevent severe illness in vulnerable infants, not to eliminate the RSV virus entirely. Sietse Nagelkerke, a pediatrician-infectiologist and immunologist, emphasizes, “The injection does not remove the RS virus, but it does ensure that far fewer children become seriously ill, and that helps enormously.”

Impact on Cases and Severity

Data indicates that babies who are still admitted to the hospital with RSV often haven’t received the shot, are too young to have been eligible, or their parents opted not to vaccinate. Zuurbier observes, “Those children look like last year’s recordings and behave similarly.” Even in cases where infants become ill despite receiving the immunization, the course of the disease appears milder. Nagelkerke states, “We think that in all these patients it would probably have been much more serious without the injection. The protection is not complete, but it is clearly present.”

Current RSV Season and Future Outlook

The current RSV season is expected to remain relatively mild. Zuurbier anticipates, “I think we have already passed the peak, which is normally around December. Now we see that the flu is on the rise, but the number of RS cases seems to be falling again.”

Understanding RSV

RSV is a common virus that typically circulates during the fall and winter months. While most children experience mild, cold-like symptoms – such as a runny nose, cough, fever, or high temperature – young babies are at a higher risk of developing more serious complications. The virus can affect the lower respiratory tract, leading to breathing difficulties and potential ICU admission, sometimes requiring ventilation.

Recent Developments in RSV Vaccination

As of May 16, 2025, three vaccines for RSV have been market approved, though the risk of RSV-hospitalization in adults remains a concern.